{"prompt": "['Trelagliptin-4002', 'Page 15 of 66', 'Version 1.0', 'November 2, 2016', 'covariates; and a treatment group as an independent variable. The level of significance will', 'be 5% (two-sided). Note that the total score for all questions in the DTR-QOL is out of the', 'scope of the analysis.', '(4) To indicate the changes in the total scores for all questions in the DTR-QOL Questionnaire', 'and DTSQ, the summary statistics and two-sided 95% CI for means per treatment group', 'will be calculated, with stratification by the following factors at the start of the treatment', 'period (Week 0):', 'Use of medication for treatment of comorbidities', 'Number of daily doses, including medication for treatment of comorbidities (<2 times', 'or >2 times)', 'Total number of daily tablets, including medication for treatment of comorbidities', '(<2 tablets or >2 tablets)', 'Number of doses of the study drug or comparative drug (once weekly, once daily or', 'twice daily)', 'Changes in the scores per question in the DTR-QOL Questionnaire at each assessment time', 'point.', 'Changes in the scores for per question in the DTSQ at each assessment time point.', '(1) Summary statistics for measurements and the changes from the baseline (Week 0) will be', 'calculated per treatment group.', 'Safety endpoints:', 'Frequency tables will be prepared for the incidences of adverse events, hypoglycemia, and', 'hospitalization (duration and number) for type 2 diabetes after the first administration of the study', 'drug or comparative drug in the \"safety population\" in each treatment group.', '<Other Endpoints>', 'Summarizations below will be performed in the \"full analysis set\" (FAS).', 'Laboratory tests', 'Summary statistics for measurements and the changes from the baseline (Week 0) will be', 'calculated per treatment group to plot the changes in means and SDs.', 'Treatment compliance', 'Treatment compliance of each study subject will be calculated and summary statistics of', 'compliance per treatment group will be presented.', 'The Basic Information on Study Subject (Your Basic Profile)', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 16 of 66', 'Version 1.0', 'November 2, 2016', 'Frequency of answers to each question at each visit will be analyzed per treatment group.', 'Rationale for the number of planned study subjects:', 'In this clinical study, to discuss the changes in the total score for all questions in the DTR-QOL', 'Questionnaire from the baseline (Week 0) to the end of the treatment period, as the primary', 'endpoint, mean changes in the daily DPP-4 inhibitor and trelagliptin groups were assumed as 14.4%', 'and 19.0%, respectively. The mean change in the daily DPP-4 inhibitor group was assumed by', 'reference to the data on a sodium glucose transporter 2 (SGLT2) inhibitor, from the previous', 'research; and that in trelagliptin group was assumed by reference to the data from the validation trial', 'of the DTR-QOL Questionnaire. The common SD was assumed as 12.1 % considering the former', 'assumption. When 5% of significance level (two-sided) is based for the analysis of the primary', 'endpoint, 110 subjects per group would be needed to ensure 80% power in comparisons between the', 'trelagliptin group and daily DPP-4 inhibitor group. As this is a study on treatment for type 2 diabetes', 'with DPP-4 inhibitors currently used in the medical setting, the number of randomized subjects was', 'established as 120 subjects per group, for a total of 240 subjects, assuming a type 2 diabetes', 'treatment discontinuation rate of 8%*.', '*Based on the results for Topic 2 of the \"Strategic Studies on the Prevention of Diabetes\"', '(JDOIT-2), the annual discontinuation rate for the \"usual care group\" without intervention is', 'approximately 8%.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 17 of 66', 'Version 1.0', 'November 2, 2016', '3.0', 'ABBREVIATION', 'AE', 'adverse event', 'COI', 'conflict of interest', 'CRO', 'contract research organization', 'DTSQ', 'Diabetes Treatment Satisfaction Questionnaire', 'DTR-QOL', 'Diabetes Therapy-Related QOL', 'FDA', 'US Food and Drug Administration', 'GCP', 'Good Clinical Practice', 'ICH', 'International Conference on Harmonization of Technical', 'Requirement for Registration on Pharmaceuticals for Human Use', 'MHRA', 'Medicines and Healthcare Products Regulatory Agency', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'QOL', 'Quality Of Life', 'SAE', 'serious adverse event', 'SAP', 'statistical analysis plan', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}